Traws Pharma (TRAW) EBT Margin (2012 - 2025)
Traws Pharma (TRAW) posted quarterly EBT Margin of 46.62% for Q2 2025, up 21635338.0% year-over-year from N/an in Q2 2024, and up 99.51% quarter-over-quarter from 9533.33% in Q1 2025.
Traws Pharma (TRAW) EBT Margin (2012 - 2025) Analysis & Trends
Traws Pharma (TRAW) has reported EBT Margin for 14 consecutive years, with 46.62% the latest figure, recorded in Q2 2025.
- In Q2 2025, EBT Margin rose 21635338.0% year-over-year to 46.62%; the TTM figure through Dec 2025 stood at 659.07% (up 6433541.0% YoY), while the FY2025 annual figure was 2065.99%, up 7723224.0% from the prior year.
- EBT Margin advanced to 46.62% in Q2 2025 per TRAW's latest filing, from 9533.33% in the prior quarter.
- Across five years, EBT Margin topped out at 46.62% in Q2 2025 and bottomed at 317173.21% in Q4 2021.
- Historically, EBT Margin has averaged 54549.29% across 5 years, with a median of 9231.53% in 2023.
- Annual changes were most pronounced in 2023 — EBT Margin soared 30604464 bps — and 2024, when it tumbled 20831228 bps.
- Traws Pharma's EBT Margin stood at 317173.21% in 2021, then rose by 1 bps to 314050.0% in 2022, then surged by 97 bps to 8005.36% in 2023, then tumbled by 78 bps to 14242.86% in 2024, then jumped by 100 bps to 46.62% in 2025.
- Business Quant data shows TRAW's EBT Margin at 46.62% in Q2 2025, 9533.33% in Q1 2025, and 14242.86% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -46.62% |
| Mar 31, 2025 | -9,533.33% |
| Dec 31, 2024 | -14,242.86% |
| Sep 30, 2024 | -17,784.38% |
| Jun 30, 2024 | -216,400.00% |
| Mar 31, 2024 | -9,690.04% |
| Dec 31, 2023 | -8,005.36% |
| Sep 30, 2023 | -8,929.74% |
| Jun 30, 2023 | -8,087.72% |
| Mar 31, 2023 | -10,958.93% |
| Dec 31, 2022 | -314,050.00% |
| Sep 30, 2022 | -9,896.49% |
| Jun 30, 2022 | -7,228.07% |
| Mar 31, 2022 | -7,393.50% |
| Dec 31, 2021 | -317,173.21% |
| Sep 30, 2021 | -7,000.00% |
| Jun 30, 2021 | -8,149.12% |
| Mar 31, 2021 | -7,317.86% |
| Dec 31, 2020 | -306,314.04% |
| Sep 30, 2020 | -9,506.06% |